Cadrenal Therapeutics Highlights CAD-1005 for Obesity and Diabetes Treatment
Cadrenal Therapeutics highlighted recent scientific findings demonstrating the potential of its first-in-class 12-lipoxygenase, 12-LOX, inhibitor, CAD-1005, to target inflammatory consequences of obesity and Type 2 diabetes. The study builds on prior animal research showing that inhibiting 12-LOX with CAD-1005 delays the onset of autoimmune diabetes in non-obese diabetic mice. The findings highlight 12-LOX as a key factor in obesity-associated inflammation and suggest that 12-LOX inhibition could be a therapeutic strategy to improve glucose homeostasis and peripheral inflammation in the setting of obesity and type 2 diabetes.
